Daewoong Pharmaceutical announced on the 31st that its botulinum toxin product ‘Nabota’ recorded sales of 115.4 billion KRW in the first half of this year. This is an approximately 28% increase compared to the 90.2 billion KRW sales in the first half of last year.
Nabota is showing growth across global markets. In the U.S. cosmetic toxin market, it achieved a market share of 14% under the brand name ‘Jeuveau’, ranking second.
The growth is also notable in South America and Southeast Asia. In Brazil, they signed an export contract worth 180 billion KRW, a tenfold increase since their first contract in 2018, strengthening their position in the largest toxin market in South America. In Thailand, they signed a new export contract three times the size of the previous one, amounting to 73.8 billion KRW.
Recently, Daewoong Pharmaceutical entered an export contract with Kuwait and will supply Nabota to five Middle Eastern countries. This marks the largest overseas expansion record among domestic toxin companies. They are quickly expanding in the premium market of the Gulf Coast, known for high demand in cosmetics and plastic surgery, by entering four out of the six countries: UAE, Saudi Arabia, Qatar, and Kuwait. In the second half of this year, they plan to actively pursue market share expansion in existing countries and entry into new ones.
Nabota is conducting various global academic activities with themes like Nabota Lift, its exclusive procedure, through conferences, webinars, and training programs. They are also expanding clinical research collaboration with local medical professionals. Yoon Joon-soo, head of the Nabota business division at Daewoong Pharmaceutical, stated, “With our premium product’s high purity and quality, we will further solidify Nabota’s competitiveness in major global markets and leap forward as a leader in the global cosmetic medical market.”